Nitrofurantoin
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1953
- First approval year
- 1953
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Nitrofurantoin
- Molecular weight
- 238.16
- Structure (SMILES)
- O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1
- berkfurin
- Berkfurin
- ceduran
- Ceduran
- dantafur
- Dantafur
- furadantin
- Furadantin
- furalan
- Furalan
- genfura
- Genfura
- macrobid
- Macrobid
- macrodantin
- Macrodantin
- nitrofurantoin
- Nitrofurantoin
- Nitrofurantoin (monohydrate/macrocrystals)
- nitrofurantoin component of macrobid
- Nitrofurantoin component of macrobid
- Nitrofurantoin component of macrobid , macrocrystalline
- nitrofurantoin component of macrobid macrocrystalline
- nitrofurantoin macrocrystalline
- Nitrofurantoin macrocrystalline
And 1 more, listed on the interactive page.
- 1 5 nitro 2 furanyl methylene amino 2 4 imidazolidenedione
- 1-((5-NITRO-2-FURANYL)METHYLENE)AMINO-2,4-IMIDAZOLIDENEDIONE
- macrobid capsules 100 mg
- macrobid component nitrofurantoin
- MACROBID COMPONENT NITROFURANTOIN
- macrobid component nitrofurantoin macrocrystalline
- MACROBID COMPONENT NITROFURANTOIN, MACROCRYSTALLINE
- Macrobid® Capsules 100 mg
- macrodantin 100 mg capsules
- Macrodantin® 100 mg Capsules
- nitrofurantoin
- Nitrofurantoin
- NITROFURANTOIN [EP MONOGRAPH]
- NITROFURANTOIN [GREEN BOOK]
- NITROFURANTOIN [HSDB]
- NITROFURANTOIN [IARC]
- nitrofurantoin [INN]
- NITROFURANTOIN [JAN]
- NITROFURANTOIN [MART.]
- NITROFURANTOIN [MI]
- NITROFURANTOIN [ORANGE BOOK]
- NITROFURANTOIN [USP MONOGRAPH]
- NITROFURANTOIN [USP-RS]
- NITROFURANTOIN [VANDF]
- Nitrofurantoin [WHO-DD]
And 42 more, listed on the interactive page.
- CAS registry numbers
- 67-20-9
- ChEMBL ID
- CHEMBL572
- InChIKey
- NXFQHRVNIOXGAQ-YCRREMRBSA-N
- PubChem compound IDs
- 6604200
- FDA ingredient codes (UNII)
- 927AH8112L
- J01XE01
- J01XE51
Sources for recorded values
- 7454
- 221129
- 235559
- Applicant
- CASPER PHARMA LLC
- Approval date
- 23 Dec 1953
- Application number
- NDA009175
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Pharmacology name
- nitrofurantoin
- Type
- Synthetic organic
- Drug name stem
- -toin
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- mitochondrial pyruvate carrier 2
- Gene symbol
- MPC2
- Protein identifier
- O95563
- Median affinity
- 5.48
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- mitochondrial pyruvate carrier 1 like
- Gene symbol
- MPC1L
- Protein identifier
- P0DKB6
- Median affinity
- 5.48
- Affinity units
- pIC50
- Mechanism
- DNA inhibitor
- Action type
- Inhibitor
- Target
- DNA
- Condition
- Bacterial Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition
- Osteomyelitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0003102
- Subject identifier
- D010019
- Condition
- Urinary Tract Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003103
- Subject identifier
- D014552
- Condition
- Cystitis
- Highest recorded phase
- 4
- Condition identifier
- EFO:1000025
- Subject identifier
- D003556
- Condition identifier
- EFO_0000771
- Condition identifier
- EFO_0003102
- Condition identifier
- EFO_0003103
- Condition identifier
- EFO_1000025
- Condition identifier
- HP_0000010
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005113
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0006032
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0100338
- Highest recorded phase
- 4
- Event
- autoimmune hepatitis
- Reports
- 88
- Reporting signal score
- 260.778
- Event
- chromaturia
- Reports
- 33
- Reporting signal score
- 44.6916
- Event
- cystitis
- Reports
- 41
- Reporting signal score
- 49.4309
- Event
- drug hypersensitivity
- Reports
- 646
- Reporting signal score
- 1,138.23
- Event
- drug reaction with eosinophilia and systemic symptoms
- Reports
- 43
- Reporting signal score
- 41.3658
- Event
- drug-induced liver injury
- Reports
- 98
- Reporting signal score
- 173.586
- Event
- dyspnoea
- Reports
- 204
- Reporting signal score
- 54.966
- Event
- eosinophilia
- Reports
- 44
- Reporting signal score
- 59.877
- Event
- hepatic fibrosis
- Reports
- 25
- Reporting signal score
- 63.353
- Event
- hepatitis
- Reports
- 53
- Reporting signal score
- 65.7503
- Event
- interstitial lung disease
- Reports
- 78
- Reporting signal score
- 88.7534
- Event
- jaundice
- Reports
- 81
- Reporting signal score
- 124.161
- Event
- liver function test abnormal
- Reports
- 50
- Reporting signal score
- 47.6468
- Event
- liver injury
- Reports
- 44
- Reporting signal score
- 67.7035
- Event
- pulmonary fibrosis
- Reports
- 91
- Reporting signal score
- 224.742
- Event
- pulmonary toxicity
- Reports
- 58
- Reporting signal score
- 164.207
- Event
- pyrexia
- Reports
- 157
- Reporting signal score
- 47.1122
- Event
- rash
- Reports
- 180
- Reporting signal score
- 55.7959
- Event
- systemic inflammatory response syndrome
- Reports
- 36
- Reporting signal score
- 96.9043
- Event
- urinary tract infection
- Reports
- 135
- Reporting signal score
- 106.592
- Event
- wheezing
- Reports
- 43
- Reporting signal score
- 38.6538
- NCT00391651
- NCT01092351
- NCT01450800
- NCT01966653
- NCT02145338
- NCT03287089
- NCT03299387
- NCT03425396
- NCT04020341
- NCT04187144
- NCT04959331
- NCT05138822
- NCT05254808
- NCT05630833
- NCT05652374
- NCT06332781
- NCT02099240
- Dose
- 100mg
- Route
- Oral
- How often
- Twice daily
Conditions of use
- Take with food
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 118.05
- Calculated partition coefficient (ALogP)
- 0.07
- Calculated partition coefficient (XLogP)
- -0.5
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 17
- Molecular formula
- C8H6N4O5
- Monoisotopic mass
- 238.03381930
- Natural product
- Yes
- 0115-1643
- 0115-1645
- 0185-0122
- 0615-8531
- 0904-7026
- 0904-7571
- 13811-719
- 16571-888
- 31722-491
- 40032-450
- 42571-393
- 42708-178
- 42708-184
- 43386-450
- 43386-641
- 43386-642
- 46708-389
- 46708-390
- 46708-391
- 47781-303
- 50268-623
- 50268-624
- 51655-948
- 52427-285
- 54348-849
And 110 more, listed on the interactive page.
- Recorded assays
- 5,797
- Active assays
- 248
- Confirmatory
- Other
- Screening
- Summary
- Anti-Infective Agents, Urinary
- Anti-Bacterial Agents
These details could not be displayed.
Related records
Trials (51)
- A Pilot Comparison of Short-course Nitrofurantoin in Females With Uncomplicated Bacterial Cystitis in the Emergency Department
- A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Kidney Stone Surgery (Percutaneous Nephrolithotomy [PCNL])
- A Study to Evaluate Efficacy and Safety of Gepotidacin in the Treatment of Uncomplicated Urinary Tract Infection (UTI)
- A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis)
- An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"
- Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract
- Asymptomatic Bacteriuria in Pregnancy in Low- and Middle-IncomE Countries
- Bioequivalence Study of Nitrofurantoin 100 mg Capsules Under Fed Conditions
- Bladder Botox UTI Antibiotic Prophylaxis
- Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.
- Clinical Trial Testing Whether Targeted Antibiotic Prophylaxis Can Reduce Infections After Cystectomy Compared to Empiric Prophylaxis
- Comparative Study to Evaluate Efficacy and Safety of Gepotidacin to Nitrofurantoin in Treatment of Uncomplicated Urinary Tract Infection (UTI)
- Comparison of Inter-appointment Pain Reduction During Root Canal Treatment in Symptomatic Apical Periodontitis by Using Intracanal Medicaments; Chlorhexidine Gel and Single Antibiotic Paste Nitrofurantoin
- Comparison of Nitrofurantoin and Calcium Hydroxide as Intracanal Medicaments in Alleviating Post-operative Pain
- COMPARISON OF NITROFURANTOIN WITH FOSFOMYCIN in TREATING CYSTITIS IN WOMEN
- Cranberry Tablets Versus Nitrofurantoin Prophylaxis for Urinary Tract Infection Prevention After Urogynecologic Surgery
- Daily Nitrofurantoin Versus Bladder Fulguration Plus Daily Nitrofurantoin for Women With Recurrent Urinary Tract Infections
- Does Treatment With Macrobid Reduce Urinary Tract Infections in Patients Receiving a Sub-Urethral Sling for Incontinence
- Effect of Nitrofurantion Used as an Intracanal Medicament
- Efficacy and Safety of Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infections in Adults
Approved for (3)
In development for (1)
- Osteomyelitis Early phase 1